Chemomab Therapeutics (NASDAQ:CMMB) Trading Up 1.9% – Here’s What Happened

Chemomab Therapeutics Ltd. Sponsored ADR (NASDAQ:CMMB)’s stock price was up 1.9% during mid-day trading on Friday . The company traded as high as $1.62 and last traded at $1.59. 34,203 shares traded hands during trading, a decline of 25% from the average daily volume of 45,326 shares. The stock had previously closed at $1.56.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings restated a “sell (e+)” rating on shares of Chemomab Therapeutics in a research note on Friday, May 8th. One equities research analyst has rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, Chemomab Therapeutics presently has a consensus rating of “Hold” and an average price target of $25.00.

Chemomab Therapeutics Trading Up 1.9%

The firm has a market cap of $11.45 million, a PE ratio of -0.72 and a beta of 0.62. The stock has a 50 day simple moving average of $1.70 and a 200-day simple moving average of $1.74.

Chemomab Therapeutics (NASDAQ:CMMB) last posted its quarterly earnings results on Thursday, May 14th. The company reported ($0.22) EPS for the quarter, missing analysts’ consensus estimates of ($0.04) by ($0.18). On average, equities research analysts expect that Chemomab Therapeutics Ltd. Sponsored ADR will post -0.4 EPS for the current year.

Institutional Investors Weigh In On Chemomab Therapeutics

Several institutional investors and hedge funds have recently modified their holdings of the stock. XTX Topco Ltd bought a new position in shares of Chemomab Therapeutics during the fourth quarter worth $31,000. Kestra Private Wealth Services LLC purchased a new position in Chemomab Therapeutics during the fourth quarter valued at $85,000. Finally, ADAR1 Capital Management LLC bought a new stake in Chemomab Therapeutics in the 4th quarter valued at $132,000. Institutional investors own 46.05% of the company’s stock.

Chemomab Therapeutics Company Profile

Chemomab Therapeutics (NASDAQ:CMMB) is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of next-generation antibody therapies. The company leverages a proprietary antibody engineering platform to generate novel bi- and multi-specific antibodies with applications in oncology, infectious diseases and inflammatory disorders. By combining cutting-edge discovery tools with translational research, Chemomab aims to advance promising candidates from early proof-of-concept through clinical development.

Among its pipeline programs, Chemomab is advancing antibody candidates designed to target key tumor antigens and pathogen-specific epitopes.